Abstract
Amyloid β protein (Aβ) is the primary component of senile plaques in Alzheimer’s disease brains and its aggregate form is neurotoxic. Aβ is generated through proteolysis of β-amyloid precursor protein (APP) by two proteases: β-secretase and γ-secretase. BACE1, the β-secretase in vivo and the key rate-limiting enzyme that initiates the formation of Aβ, is an attractive drug target for AD therapy. Our previous study demonstrated that BACE1 is ubiquitinated and its degradation and effect on APP cleaving process are mediated by the ubiquitin-proteasome pathway. However, the specific underlying mechanism is still not well defined. In present study, we determined the specific binding sites responsible for the proteasomal degradation of BACE1. Ten fragments of human BACE1 cDNA with each of them containing 1 to 3 Lys codons were cloned, and HEK293 cells transfected with these recombinant plasmids were treated with specific proteasome inhibitor lactacystin. The protein levels of fragment-3 (Pro149-Leu180), -4 (IIe179-Ser230) and -8 (Met349-Arg400) were significantly increased by lactacystin treatment, and immunocytochemical staining results showed that fragment-3, -4 and -8 proteins were colocalized with ubiquitin. Site-directed mutagenesis at Lys203 and Lys382 of BACE1 abolished the proteasomal degradation of BACE1 and affected APP processing at β site and Aβ production. Taken together, our study demonstrated that BACE1 Lys203 and Lys382 are essential for its proteasomal degradation, and the results may advance our understanding of regulation of BACE1 and APP processing by the ubiquitin proteasome system in AD pathogenesis and shed new insights on its pharmaceutical potential.
Keywords: APP, BACE1, ubiquitination, Alzheimer.
Current Alzheimer Research
Title:Lys203 and Lys382 are Essential for the Proteasomal Degradation of BACE1
Volume: 9 Issue: 5
Author(s): Rong Wang, Zhengxin Ying, Juan Zhao, Yanyan Zhang, Ran Wang, Hong Lu, Yulin Deng, Weihong Song3,* and, Weihong Song and Hong Qing
Affiliation:
Keywords: APP, BACE1, ubiquitination, Alzheimer.
Abstract: Amyloid β protein (Aβ) is the primary component of senile plaques in Alzheimer’s disease brains and its aggregate form is neurotoxic. Aβ is generated through proteolysis of β-amyloid precursor protein (APP) by two proteases: β-secretase and γ-secretase. BACE1, the β-secretase in vivo and the key rate-limiting enzyme that initiates the formation of Aβ, is an attractive drug target for AD therapy. Our previous study demonstrated that BACE1 is ubiquitinated and its degradation and effect on APP cleaving process are mediated by the ubiquitin-proteasome pathway. However, the specific underlying mechanism is still not well defined. In present study, we determined the specific binding sites responsible for the proteasomal degradation of BACE1. Ten fragments of human BACE1 cDNA with each of them containing 1 to 3 Lys codons were cloned, and HEK293 cells transfected with these recombinant plasmids were treated with specific proteasome inhibitor lactacystin. The protein levels of fragment-3 (Pro149-Leu180), -4 (IIe179-Ser230) and -8 (Met349-Arg400) were significantly increased by lactacystin treatment, and immunocytochemical staining results showed that fragment-3, -4 and -8 proteins were colocalized with ubiquitin. Site-directed mutagenesis at Lys203 and Lys382 of BACE1 abolished the proteasomal degradation of BACE1 and affected APP processing at β site and Aβ production. Taken together, our study demonstrated that BACE1 Lys203 and Lys382 are essential for its proteasomal degradation, and the results may advance our understanding of regulation of BACE1 and APP processing by the ubiquitin proteasome system in AD pathogenesis and shed new insights on its pharmaceutical potential.
Export Options
About this article
Cite this article as:
Wang Rong, Ying Zhengxin, Zhao Juan, Zhang Yanyan, Wang Ran, Lu Hong, Deng Yulin, Song3,* and Weihong, Song Weihong and Qing Hong, Lys203 and Lys382 are Essential for the Proteasomal Degradation of BACE1, Current Alzheimer Research 2012; 9 (5) . https://dx.doi.org/10.2174/156720512800618026
DOI https://dx.doi.org/10.2174/156720512800618026 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emerging Therapeutic Targets in Regenerative Medicine for the Treatment of Diabetes Mellitus: A Patent Literature Review
Recent Patents on Regenerative Medicine On the Pathogenesis and Neuroprotective Treatment of Parkinson Disease: What have we Learned from the Genetic Forms of this Disease?
Current Medicinal Chemistry Permeating the Blood Brain Barrier and Abrogating the Inflammation in Stroke: Implications for Stroke Therapy
Current Pharmaceutical Design Probenecid: An Emerging Tool for Neuroprotection
CNS & Neurological Disorders - Drug Targets Chelating Agents for Neurodegenerative Diseases
Current Medicinal Chemistry Inhibition of Opioid Receptor Mediated G-Protein Activity After Chronic Administration of Kynurenic Acid and its Derivative without Direct Binding to Opioid Receptors
CNS & Neurological Disorders - Drug Targets Steroid Receptor-Associated Immunophilins: Candidates for Diverse Drug-Targeting Approaches in Disease
Current Molecular Pharmacology Disease-Modifying Therapies in Frontotemporal Lobar Degeneration
Current Medicinal Chemistry Multivalent & Multifunctional Ligands to β-Amyloid
Current Pharmaceutical Design New Perspectives for the Diagnosis of Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) The Impact of Small Heat Shock Proteins (HspBs) in Alzheimer’s and Other Neurological Diseases
Current Pharmaceutical Design Alterations in Glucose Metabolism in Alzheimer's Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Role of Uric Acid and Methyl Derivatives in the Prevention of Age-Related Neurodegenerative Disorders
Current Topics in Medicinal Chemistry The Immunoproteasome: An Emerging Therapeutic Target
Current Topics in Medicinal Chemistry Proteasome Inhibitors Therapeutic Strategies for Cancer
Recent Patents on Anti-Cancer Drug Discovery Editorial [Hot Topic: The Medicinal Chemistry of Hybrid-Based Drugs Targeting Multiple Sites of Action (Guest Editors: Jose Marco-Contelles, & Elena Soriano)]
Current Topics in Medicinal Chemistry Protein Cysteine Modifications: (1) Medicinal Chemistry for Proteomics
Current Medicinal Chemistry Transgenic Mouse Models of Tauopathy in Drug Discovery
CNS & Neurological Disorders - Drug Targets Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease
Current Alzheimer Research Cell Death and Apoptosis in Ostearthritic Cartilage
Current Drug Targets